| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Nuclear Medicine |
1 From the Departments of Diagnostic Radiology (J.A., H.I., N.O., N.S., K.E.), Orthopedic Surgery (H.W., T.S., K.T.), and Nuclear Medicine (T.I., K.E.), Gunma University School of Medicine, 3-39-22 Showa-machi, Maebashi 371-8511, Japan. From the 2000 RSNA scientific assembly. Received May 11, 2000; revision requested June 19; revision received August 4; accepted September 12. Address correspondence to J.A. (e-mail: junaoki@showa.gunma-u.ac.jp).
PURPOSE: To evaluate the standardized uptake value (SUV) of 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) at positron emission tomography (PET) in the differentiation of benign from malignant bone lesions.
MATERIALS AND METHODS: Fifty-two (19 malignant, 33 benign) primary bone lesions were examined with FDG PET prior to tissue diagnosis. The SUVs were calculated and compared between benign and malignant lesions and among histologic subgroups that included more than four cases.
RESULTS: There was a statistically significant difference in SUV between benign (2.18 ± 1.52 [SD]) and malignant (4.34 ± 3.19) lesions in total (P = .002). However, giant cell tumors (n = 5; SUV, 4.64 ± 1.05) showed significantly higher SUV than chondrosarcomas (n = 7; SUV, 2.23 ± 0.74) (P = .036, adjusted for multiple comparisons) and had no statistically significant difference in SUV compared with osteosarcomas (n = 6; SUV, 3.07 ± 0.96) (P = .171). There was no statistically significant difference in SUV between fibrous dysplasias (n = 6; SUV, 2.05 ± 0.98) and osteosarcoma (P = .127) or chondrosarcomas (P = .667). Although the number of cases was small, three chondroblastomas, one sarcoidosis, and one Langerhans cell histiocytosis showed levels of FDG accumulation as high as that of osteosarcomas.
CONCLUSION: Radiologists should be aware of the high accumulation of FDG in some benign bone lesions, especially histiocytic or giant cell–containing lesions. Consideration of histologic subtypes should be included in analysis of SUV at FDG PET of primary bone tumors.
Index terms: Bone neoplasms, diagnosis, 40.31, 40.32 • Bone neoplasms, PET, 40.12163 • Bone neoplasms, radionuclide studies, 40.12163 • Fluorine, radioactive
This article has been cited by other articles:
|
|
 |
|
  E. M. Chung, M. D. Murphey, C. S. Specht, R. Cube, and J. Smirniotopoulos From the Archives of the AFIP * Pediatric Orbit Tumors and Tumorlike Lesions: Osseous Lesions of the Orbit RadioGraphics, July 1, 2008; 28(4): 1193 - 1214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Buck, K. Herrmann, C. M. z. Buschenfelde, M. E. Juweid, M. Bischoff, G. Glatting, G. Weirich, P. Moller, H.-J. Wester, K. Scheidhauer, et al. Imaging Bone and Soft Tissue Tumors with the Proliferation Marker [18F]Fluorodeoxythymidine Clin. Cancer Res., May 15, 2008; 14(10): 2970 - 2977. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Bredella, M. Torriani, F. Hornicek, H. A. Ouellette, W. E. Plamer, Z. Williams, A. J. Fischman, and S. R. Plotkin Value of PET in the Assessment of Patients with Neurofibromatosis Type 1 Am. J. Roentgenol., October 1, 2007; 189(4): 928 - 935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Biswal, D. L. Resnick, J. M. Hoffman, and S. S. Gambhir Molecular Imaging: Integration of Molecular Imaging into the Musculoskeletal Imaging Practice Radiology, September 1, 2007; 244(3): 651 - 671. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kuwahara, S. Izawa, H. Murabe, N. Murakami, T. Yokota, Y. Wani, K. Notohara, C. Tsukayama, T. Ishimori, and Y. Watanabe Increased 18F-Fluorodeoxyglucose Uptake in a Brown Tumor in a Patient with Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2408 - 2409. [Full Text] [PDF]
|
|
|
|
|
|
S. W. Hetts, S. D. Hilchey, R. Wilson, and B. Franc Case 110: Nonossifying Fibroma Radiology, April 1, 2007; 243(1): 288 - 292. [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Heck Jr., T. D. Peabody, and M. A. Simon Staging of Primary Malignancies of Bone CA Cancer J Clin, November 1, 2006; 56(6): 366 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Abouzied, E. S. Crawford, and H. A. Nabi 18F-FDG Imaging: Pitfalls and Artifacts J. Nucl. Med. Technol., September 1, 2005; 33(3): 145 - 155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Even-Sapir Imaging of Malignant Bone Involvement by Morphologic, Scintigraphic, and Hybrid Modalities J. Nucl. Med., August 1, 2005; 46(8): 1356 - 1367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Y.-I. Lee, J. Yu, S.-S. Chang, R. Fawwaz, and M. V. Parisien Diagnostic Value and Limitations of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography for Cartilaginous Tumors of Bone J. Bone Joint Surg. Am., December 1, 2004; 86(12): 2677 - 2685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Boellaard, N. C. Krak, O. S. Hoekstra, and A. A. Lammertsma Effects of Noise, Image Resolution, and ROI Definition on the Accuracy of Standard Uptake Values: A Simulation Study J. Nucl. Med., September 1, 2004; 45(9): 1519 - 1527. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. G. Strauss, A. Dimitrakopoulou-Strauss, D. Koczan, L. Bernd, U. Haberkorn, V. Ewerbeck, and H.-J. Thiesen 18F-FDG Kinetics and Gene Expression in Giant Cell Tumors J. Nucl. Med., September 1, 2004; 45(9): 1528 - 1535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Murphey, E. A. Walker, A. J. Wilson, M. J. Kransdorf, H. T. Temple, and F. H. Gannon From the Archives of the AFIP: Imaging of Primary Chondrosarcoma: Radiologic-Pathologic Correlation RadioGraphics, September 1, 2003; 23(5): 1245 - 1278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Brenner, K. H. Bohuslavizki, and J. F. Eary PET Imaging of Osteosarcoma J. Nucl. Med., June 1, 2003; 44(6): 930 - 942. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Hoffmann, H Vogelsang, K Kletter, G Zettinig, A Chott, and M Raderer 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma Gut, March 1, 2003; 52(3): 347 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Bredella, G. R. Caputo, and L. S. Steinbach Value of FDG Positron Emission Tomography in Conjunction with MR Imaging for Evaluating Therapy Response in Patients with Musculoskeletal Sarcomas Am. J. Roentgenol., November 1, 2002; 179(5): 1145 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Franzius, S. Bielack, S. Flege, J. Sciuk, H. Jurgens, and O. Schober Prognostic Significance of 18F-FDG and 99mTc-Methylene Diphosphonate Uptake in Primary Osteosarcoma J. Nucl. Med., August 1, 2002; 43(8): 1012 - 1017. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| RADIOLOGY | RADIOGRAPHICS | RSNA JOURNALS ONLINE |
